Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | MB-106 |
Synonyms | |
Therapy Description |
MB-106 are autologous T-lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting CD20, and containing CD28 co-stimulatory and TNFRSF9 (4-1BB) and CD3zeta signaling domains, which potentially induce killing of tumor cells expressing CD20 (Blood (2021) 138 (Supplement 1): 3872; NCI Drug Dictionary). |